Rajani Dinavahi - 01 Apr 2026 Form 3 Insider Report for ARDELYX, INC. (ARDX)

Reporting relationship: Chief Medical Officer
Issuer ticker: ARDX
Reported as of: 01 Apr 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 03 Apr 2026, 16:16:22 UTC
Source filing: View source filing
Reporting owner signature: /s/ Shannon Moesaa, Attorney-in-Fact for Rajani Dinavahi

Key filing fact

Rajani Dinavahi filed Form 3 for ARDELYX, INC. (ARDX) on 03 Apr 2026.

Key facts

This page summarizes Rajani Dinavahi's Form 3 filing for ARDELYX, INC. (ARDX).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Apr 2026, 16:16.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002125089 Primary reporting owner

Dinavahi Rajani

Relationship: Chief Medical Officer
Address: C/O ARDELYX, INC., 400 FIFTH AVE, SUITE 210, WALTHAM
Signature: /s/ Shannon Moesaa, Attorney-in-Fact for Rajani Dinavahi
Signature date: 03 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARDX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 201,000
Date: 01 Apr 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARDX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 301,000
Exercise price: $6.11
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof.

Footnote F2

Twenty Five Percent (25%) of the shares subject to the option vest on April 1, 2027 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

SEC remarks

Exhibit 24.1 - Power of Attorney